A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period

The purpose of this study is to evaluate the safety, tolerability and efficacy of NRL001 in the treatment of faecal incontinence, compared against placebo

Study Overview

• Status: Completed
• Conditions: Faecal Incontinence
• Intervention / Treatment: Drug: Placebo; Drug: 1R, 2S-methoxamine hydrochloride

• Study Type: Interventional
• Enrollment (Actual): 417
• Phase: Phase 2

Contacts and Locations

Study Locations

• Czech Republic
  • Brno, Czech Republic, 620 00
    • Fakultní Nemocnice Brno
  • Hradec Kralove, Czech Republic, 500 02
    • Gastroenterologie S R O
  • Liberec, Czech Republic, 130 00
    • Krajska Nemocnice Liberec
  • Prague, Czech Republic, 180 00
    • Fakultni Nemocnice Na Bulovce, Gynekologicko-Porodnicka Klinika
  • Praha, Czech Republic, 100 34
    • Fakulni Nemocnice Kralovske
  • Praha, Czech Republic, 130 00
    • Egk S.R.O Sanatoriu< Sv
  • Praha, Czech Republic, 130 00
    • GEP Clinic S.R.O
  • Praha, Czech Republic, 150 06
    • Fakultni Nemocnice V Motole
• France
  • Bordeaux, France, 33000
    • CHU Bordeaux - Hopital St Andre
  • Lyon, France, 69003
    • Chu Lyon Groupement Hospitalier Edouard Herriot
  • Nantes, France, 44093
    • Chu Nantes - Hotel Dieu - Institut Des Maladies De L'Appareil Digestif (IMAD)
  • Rennes, France
    • Dr Laurent Siproudhis
  • Rouen, France, 76031
    • Chu Rouen - Hopital De Charles Nicolle
• Germany
  • Berlin, Germany, 14163
    • Zentrum Fur Darm-Und Beckenchirurgie
  • Berlin, Germany, 14193
    • Martin-Luther-Krankenhaus
  • Heidelberg, Germany, 69115
    • Universitats-Frauenklink
• Hungary
  • Budapest, Hungary, H-1136
    • PMC Pannon Medical Center
  • Budapest, Hungary, H-1183
    • Polyclinic for Outpatients, Szakrendelo Intezet
  • Debrecen, Hungary, 4032
    • University of Debrecen, Medical and Health Science Center
  • Szeged, Hungary, 6720
    • University of Szeged, Albert Szent-Gyorgyi Clinical Center, Faculty of Medicine
  • Vac Argenti, Hungary, H-2600
    • Javorszky Odon Hopsital
  • Veszprem, Hungary, H-8200
    • Csolnoky Ferenc Veszprem
• Italy
  • Milan, Italy, 20132
    • Chirurgia Gastroenterologica
  • Milano, Italy, 20159
    • Casa Di Cura San Pio X
  • Pordenone, Italy, 33170
    • Seconda Unita Operativa Di Chirurgia Generale
  • Rome, Italy, 00161
    • Dipartimento Emergenza Urgenza
  • Rome, Italy, 00161
    • Unita Operativa Complessa Gastroenteroloogia A
  • Rome, Italy
    • Unita Operativa Complessa Patologia Chirurgica A Indirizzo Gastroenterologico
• Poland
  • Bydgoszcz, Poland, 85-079
    • NZOZ Vitamed
  • Gdow, Poland, 32-420
    • General And Proctology Surgeon
  • Glowno, Poland, 95-015
    • Centrum Medyczne, Wyzszej Szkoly Informatycznej
  • Katowice, Poland, 40-079
    • Nzoz Mekmed S.C. Przychondnia Lekarska
  • Lodz, Poland, 94-238
    • Nzoz Mikomed
  • Ostroda, Poland, 14-100
    • Osrodek Badawczo - Leczniczy Zbigniew Zegota
  • Sopot, Poland, 81-756
    • Endoskopia
  • Swidnik, Poland, 21-040
    • Lubelskie Centrum Diagnostyczne
  • Warsaw, Poland, 01-231
    • Lecznica Prosen SMO Private Medical Health Care Centre
  • Wroclaw, Poland, 53-333
    • Ars Medica SC
• Spain
  • Barcelona, Spain, 08036
    • Hospital Clínic de Barcelona
  • Barcelona, Spain, 08035
    • Hospital Valle de Hebron
  • Malaga, Spain, 29603
    • USP, Hospital De Marbella
  • Mataro, Spain, 08304
    • Hospital de Mataro
  • Zaragoza, Spain, 50009
    • Hospital Clinico Universtiaria Lozana Blesa
• Sweden
  • Malmo, Sweden, 205 02
    • Pelvic Floor Centre
  • Orebro, Sweden, 70362
    • Kirurgiska Kliniken Universitetssjukhuset
  • Stockholm, Sweden, 141 86
    • Enheten For Nedre Abdominell Kirurgi
  • Uppsala, Sweden, 75185
    • Institute of SUrgical Sciences
• United Kingdom
  • London, United Kingdom, NW1 2BU
    • University College Hospital
  • London, United Kingdom, HA1 3UJ
    • St Mark's Hospital
  • Nottingham, United Kingdom, NG7 2UH
    • Queens Medical Centre
  • Sheffield, United Kingdom, S5 7AU
    • Nothern General Hopsital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• An ultrasound assessment of the internal anal sphincter within the previous 12 months confirming an intact circular internal sphincter with minimal scars (maximum 60 degrees scarring circumferentially).
• Diagnosis of faecal incontinence with a Wexner score of 8 - 20 inclusive at Visit 1 - Screening Visit.
• Historical clinical evidence (past 6 months prior to Visit 1 - Screening Visit) of faecal incontinence episodes (solids, liquid, gas or mucus).
• Greater than or equal to two faecal incontinence episodes (solids, liquid, gas or mucus) per week during the 4 week historical period prior to Visit 1 - Screening Visit.
• Able and willing to receive rectal examinations and treatments.
• Patients must be aged >18 without significant acute or uncontrolled chronic disease.
• Patients must understand the purpose and risks of the study and be able to provide written informed consent and willing, able and competent to complete the entire study and comply with study instructions as defined in the protocol.
• Female patients must be postmenopausal (for at least one year and confirmed by serum FSH at screening), or surgically sterile, practicing true sexual abstinence, or using Investigator-approved methods of contraception throughout the study until after the post study physical examination and have a negative pregnancy test at screening.
• Sexually active male patients must use condoms with their partners throughout the study and for 90 days after completion of the study in addition to their partner's normal mode of contraception.
• Male patients must not donate sperm during the study and for 90 days after the completion of the study.
• Patients taking any continuous medication need to have been on a stable regimen for at least 1 month prior to Visit 1 - Screening Visit.

Exclusion Criteria:

• External anal sphincter disruption related to faecal incontinence caused by trauma.
• Patients with complicating gastrointestinal (GI) disease including those with inflammatory bowel diseases, patients that have received radiotherapy or surgery for anal cancer, patients with rectal prolapse, transanal surgery.

• Relevant history of or presence of any significant or uncontrolled cardiovascular risk including:

  1. Systolic > 160mmHg or Diastolic > 100mmHg. Patients on a stable regimen for > 3 months with controlled hypertension prior to Visit 1 - Screening Visit (Systolic < 140mmHg or Diastolic < 90mmHg) can be included.
  2. Abnormal 24 hour Screening Holter: corrected QT interval (QTcf) prolongation with cut-off values of >460 ms for females and >430 ms for males, acute arrhythmia, nocturnal bradycardia with heart rate (HR) < 40bpm, atrial fibrillation, AV block Type II and III, Sick Sinus Syndrome, vasovagal syncope.
  3. Fixed cardiac output states (severe aortic stenosis (AS), hypertrophic obstructive cardiomyopathy (HOCM).
  4. Significant mitral regurgitation (MR).
  5. Cardiac failure (New York Heart Association (NYHA) stage II-IV).
• Severe or uncontrolled asthma or chronic obstructive pulmonary disease determined by clinical history, physical examination, lung function tests or exercise tolerance
• Chronic liver disease (e.g. liver cirrhosis, chronic hepatitis, severe hepatic insufficiency).
• Vascular claudication after <50 metres walking distance.
• Severe renal impairment defined as glomerular filtration rate (GFR) ≤ 30 ml/min, uncontrolled and reno-vascular end stage renal disease.
• Patients with diabetic polyneuropathies.
• Any type of chronic diarrhoea or frequent diarrhoea (defined as >5 loose stools per day).
• Faecal impaction and overflow diarrhoea.
• Male patients with clinically diagnosed prostatic hyperplasia.
• Clinically significant electrolyte abnormalities, e.g. clinically significant low/high potassium and low sodium.
• Presence of clinical symptomatic haemorrhoids (grade III and IV), anal fissures or anorectal fistulas.
• Less than 2 episodes of faecal incontinence (solids, liquid, gas or mucus) per week during the 4 week historical period prior to Visit 1 - Screening Visit.
• Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
• Known history of allergy to methoxamine or any other ingredients of the Investigational Medicinal Product.
• Patients who, in the opinion of the Investigator, are unsuitable for participation in the study due to any dependencies, general medical conditions or significant illness within two weeks prior to randomisation.
• Use of any disallowed concomitant medication or other medication that the Investigator believes may affect the study including over-the-counter (OTC) products within 30 days prior to the Investigational Medicinal Product administration.
• A personal or family history of QTcf prolongation or sudden death.
• Patients taking Loperamide (2mg) >8 tablets per day for faecal incontinence either alone or in combination with codeine phosphate and/or paracetamol (8/500mg).
• Patients using any device for the treatment of faecal incontinence.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo; Placebo 2g Suppository	Drug: Placebo
Active Comparator: NRL001 5mg; 5mg NRL001 in a 2g suppository	Drug: 1R, 2S-methoxamine hydrochloride; Other Names: NRL001
Active Comparator: NRL001 7.5mg; 7.5mg NRL001 in a 2g suppository	Drug: 1R, 2S-methoxamine hydrochloride; Other Names: NRL001
Active Comparator: NRL001 10mg; 10mg NRL001 in a 2g suppository	Drug: 1R, 2S-methoxamine hydrochloride; Other Names: NRL001

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Evaluate the efficacy of NRL001 in faecal incontinence by assessing the improvement of the incontinence status after 4 weeks of treatment compared to baseline by means of the Wexner score	Up to 8 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
To provide data on the efficacy of NRL001 in patients with faecal incontinence over an 8 week treatment period	8 weeks
To provide preliminary data on the safety and tolerability of NRL001 (5mg, 7.5mg and 10mg) over an 8 week treatment period compared to placebo	8 weeks
To evaluate the population pharmacokinetics and to establish any pharmacokinetic/pharmacodynamic relationship with adverse events	8 weeks
To evaluate the dose-response relationship in order to identify the appropriate dose(s) of NRL001 for future studies	8 weeks
To evaluate the effect of treatment according to the patient's Faecal Incontinence Quality of Life questionnaire at 4 and 8 weeks	8 weeks
To evaluate the effect of treatment according to the Vaizey score at 4 and 8 weeks	8 weeks

Collaborators and Investigators

• Sponsor: Norgine
• Investigators: Principal Investigator: Laurent Siproudhis, MD, Hôpital Pontchaillou

Study record dates

Study Major Dates

• Study Start: February 1, 2012
• Primary Completion (Actual): December 1, 2013
• Study Completion (Actual): September 1, 2014

Study Registration Dates

• First Submitted: August 1, 2012
• First Submitted That Met QC Criteria: August 1, 2012
• First Posted (Estimate): August 3, 2012

Study Record Updates

• Last Update Posted (Estimate): June 9, 2015
• Last Update Submitted That Met QC Criteria: June 8, 2015
• Last Verified: June 1, 2015

More Information

Terms related to this study

• Keywords: Faecal Incontinence; Suppository; Wexner score
• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Intestinal Diseases; Rectal Diseases; Fecal Incontinence; Physiological Effects of Drugs; Adrenergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Adrenergic alpha-Agonists; Adrenergic Agonists; Sympathomimetics; Vasoconstrictor Agents; Adrenergic alpha-1 Receptor Agonists; Methoxamine
• Other Study ID Numbers: NRL001-01/2011 (SEFI)